Evidence map›Paper›PMID 33913265›Full record

ArticleBrain tumor research and treatment2021

The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1.

Hong In Yoon, Chan Woo Wee, Young Zoon Kim, Youngbeom Seo, Jung Ho Im, Yun Sik Dho, Kyung Hwan Kim, Je Beom Hong, Jae Sung Park, Seo Hee Choi and 20 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain tumor research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 19 institutions in 1 country.

Hong In YoonDepartment of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2106-6856
Chan Woo WeeDepartment of Radiation Oncology, SMG-SNU Boramae Medical Center, Seoul, Korea.
Young Zoon KimDivision of Neurooncology and Department of Neurosurgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Youngbeom SeoDepartment of Neurosurgery, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea.
Jung Ho ImDepartment of Radiation Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Yun Sik DhoDepartment of Neurosurgery, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
Kyung Hwan KimDepartment of Neurosurgery, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.
Je Beom HongDepartment of Neurosurgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jae Sung ParkDepartment of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Seo Hee ChoiDepartment of Radiation Oncology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
Min Sung KimDepartment of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Jangsup MoonDepartment of Genomic Medicine, Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Kihwan HwangDepartment of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Ji Eun ParkDepartment of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jin Mo ChoDepartment of Neurosurgery, Catholic Kwandong University, International St. Mary's Hospital, Incheon, Korea.
Wan Soo YoonDepartment of Neurosurgery, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Se Hoon KimDepartment of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Young Il KimDepartment of Neurosurgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
Ho Sung KimDepartment of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kyoung Su SungDepartment of Neurosurgery, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Korea.
Jin Ho SongDepartment of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Min Ho LeeDepartment of Neurosurgery, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, Korea.
Myung Hoon HanDepartment of Neurosurgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Se Hoon LeeDivision of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jong Hee ChangDepartment of Neurosurgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Do Hoon LimDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Chul Kee Park *Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. nschpark@snu.ac.kr.ORCID https://orcid.org/0000-0002-2350-9876
Youn Soo Lee *Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. lys9908@catholic.ac.kr.ORCID https://orcid.org/0000-0002-1653-6315
Ho Shin Gwak *Department of Cancer Control, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea. nsghs@ncc.re.kr.ORCID https://orcid.org/0000-0001-7175-4553
KSNO Guideline Working Group
Ulsan College · KRSeoul National University Hospital · KRYonsei University · KRSamsung Medical Center · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRThe Catholic University of Korea St. Vincent's Hospital · KRCatholic Kwandong University International St. Mary's Hospital · KRCHA University Bundang Medical Center · KRChungbuk National University Hospital · KRChungnam National University Hospital · KRDong-A University Hospital · KRHanyang University Guri Hospital · KRKangbuk Samsung Hospital · KRNational Cancer Center · KRSeoul National University Bundang Hospital · KRSNUH SMG-SNU Boramae Medical Center · KRThe Catholic University of Korea Incheon St. Mary's Hospital · KRThe Catholic University of Korea Uijeongbu St. Mary's Hospital · KRYeungnam University College

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere have been no guidelines for the management of adult patients with diffuse midline glioma (DMG), H3K27M-mutant in Korea since the 2016 revised WHO classification newly defined this disease entity. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, had begun preparing guidelines for DMG since 2019.

methodsThe Working Group was composed of 27 multidisciplinary medical experts in Korea. References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL using specific and sensitive keywords as well as combinations of keywords. As 'diffuse midline glioma' was recently defined, and there was no international guideline, trials and guidelines of 'diffuse intrinsic pontine glioma' or 'brain stem glioma' were thoroughly reviewed first.

resultsThe core contents are as follows. The DMG can be diagnosed when all of the following three criteria are satisfied: the presence of the H3K27M mutation, midline location, and infiltrating feature. Without identification of H3K27M mutation by diagnostic biopsy, DMG cannot be diagnosed. For the primary treatment, maximal safe resection should be considered for tumors when feasible. Radiotherapy is the primary option for tumors in case the total resection is not possible. A total dose of 54 Gy to 60 Gy with conventional fractionation prescribed at 1-2 cm plus gross tumor volume is recommended. Although no chemotherapy has proven to be effective in DMG, concurrent chemoradiotherapy (± maintenance chemotherapy) with temozolomide following WHO grade IV glioblastoma's protocol is recommended.

conclusionThe detection of H3K27M mutation is the most important diagnostic criteria for DMG. Combination of surgery (if amenable to surgery), radiotherapy, and chemotherapy based on comprehensive multidisciplinary discussion can be considered as the treatment options for DMG.

Indexed as

Diffuse midline gliomaGuidelineKorean Society for Neuro-OncologyPractice

Identifiers

PMID33913265
PMCPMC8082289
OpenAlexW3157115460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.